Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI

On 18th September, Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055. ISM001-055 is a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase) and was designed utilizing generative AI to treat idiopathic pulmonary fibrosis (IPF). The study met both its primary endpoint of safety and its secondary efficacy endpoints, demonstrating dose-dependent response in forced vital capacity (FVC), a critical measure of lung function in IPF patients. ISM001-055’s positive Phase IIa results represent a proof-of-concept success for AI-driven drug discovery.